Subject(s)
Amdinocillin Pivoxil/therapeutic use , Amdinocillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Microbial Sensitivity Tests , Urinary Tract Infections/microbiology , Administration, Oral , Amoxicillin/therapeutic use , Ampicillin/therapeutic use , Drug Combinations/therapeutic use , Humans , Nalidixic Acid/therapeutic use , Nitrofurantoin/therapeutic use , Prospective Studies , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination , Urinary Tract Infections/drug therapyABSTRACT
The in-vitro sensitivity to ampicillin, cotrimoxazole, nitrofuratoin, nalidixic acid and mecillinam was determined for 511 organisms isolated from 399 consecutive urine specimens. Urine specimens were divided into those of hospital in-patient origin (group B). Group B organisms were more sensitive than group A organisms. Over 75 percent of all group B organisms were sensitive to nitrofurantoin, nalidixic acid and mecillinam. Organisms resistant to multiple antibiotics were more frequently isolated from group A catheterized patients and are now less frequently isolated than in 1983. The antibiotic implications of these findings are discussed (AU)
Subject(s)
Humans , Amdinocillin Pivoxil/therapeutic use , Anti-Bacterial Agents/therapeutic use , Microbial Sensitivity Tests , Urinary Tract Infections/microbiology , Amdinocillin/therapeutic use , Administration, Oral , Amoxicillin/therapeutic use , Ampicillin/therapeutic use , Drug Combinations/therapeutic use , Nalidixic Acid/therapeutic use , Nitrofurantoin/therapeutic use , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic use , Urinary Tract Infections/drug therapy , Prospective StudiesABSTRACT
The in-vitro sensitivity to ampicillin, cotrimoxazole, nitrofuratoin, nalidixic acid and mecillinam was determined for 511 organisms isolated from 399 consecutive urine specimens. Urine specimens were divided into those of hospital in-patient origin (group A) and those from comunity patients(group B). Group B organisms were more sensitive than group A organisms. Over 75% of all group B organisms were sensitive to nitrofurantoin, nalidixic acid and mecillinam. Organisms resistant to multiple antibiotics were more frequently isolated from group A catheterized patients and are now less frequently isolated than in 1983. The antibiotic implications of these findings are discussed
Subject(s)
Humans , Microbial Sensitivity Tests , Amdinocillin/therapeutic use , Amdinocillin Pivoxil/therapeutic use , Administration, Oral , Urinary Tract Infections , Amoxicillin/therapeutic use , Ampicillin/therapeutic use , Nalidixic Acid/therapeutic use , Anti-Bacterial Agents/therapeutic use , Drug Combinations/therapeutic use , Nitrofurantoin/therapeutic useABSTRACT
A randomized double-blind study was carried out in a group of Danish students visiting Mexico for 2 weeks to investigate the efficacy of mecillinam when given orally in preventing travellers' diarrhoea. The subjects took either 200 mg mecillinam daily as a single dose or placebo for 14 days. Nine (56%) out of 16 taking placebo and 3 (19%) out of 16 taking mecillinam developed travellers' diarrhoea (p less than 0.05). The pathogenic aetiology was not ascertained. A complete change in the Enterobacteriaceae flora took place during travel. A highly antibiotic-resistant Enterobacteriaceae flora was acquired in Mexico in subjects on mecillinam prophylaxis as well as on placebo. Selection of mecillinam-resistant bacteria was minimal.